Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
graft-versus-host disease
Pharma
Sanofi inks $1.5B deal for Sino Biopharm's novel asset
Sanofi is committing $1.53 billion to license a first-in-class JAK/ROCK inhibitor from Sino Biopharm with eyes on both hematology and immunology.
Angus Liu
Mar 4, 2026 3:00am
After two rejections, FDA approves Mesoblast's cell therapy
Dec 19, 2024 11:24am
Syndax strikes $350M funding deal with Royalty Pharma
Nov 5, 2024 10:50am
Incyte, Syndax bag FDA nod for potential GvHD blockbuster
Aug 14, 2024 5:15pm
Incyte nets soccer legend Mia Hamm for GvHD awareness
Aug 31, 2023 7:40am
J&J, AbbVie's Imbruvica is first drug to treat kids with cGVHD
Aug 25, 2022 9:37am
